205 related articles for article (PubMed ID: 14699120)
1. Tyrosine kinase, p56lck-induced cell motility, and urokinase-type plasminogen activator secretion involve activation of epidermal growth factor receptor/extracellular signal regulated kinase pathways.
Mahabeleshwar GH; Das R; Kundu GC
J Biol Chem; 2004 Mar; 279(11):9733-42. PubMed ID: 14699120
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase p56lck regulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through tyrosine phosphorylation of IkappaBalpha following hypoxia/reoxygenation.
Mahabeleshwar GH; Kundu GC
J Biol Chem; 2003 Dec; 278(52):52598-612. PubMed ID: 14534291
[TBL] [Abstract][Full Text] [Related]
3. Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells.
Das R; Mahabeleshwar GH; Kundu GC
J Biol Chem; 2004 Mar; 279(12):11051-64. PubMed ID: 14704150
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia regulates cross-talk between Syk and Lck leading to breast cancer progression and angiogenesis.
Chakraborty G; Rangaswami H; Jain S; Kundu GC
J Biol Chem; 2006 Apr; 281(16):11322-31. PubMed ID: 16474166
[TBL] [Abstract][Full Text] [Related]
5. Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation.
Rangaswami H; Bulbule A; Kundu GC
J Biol Chem; 2004 Sep; 279(37):38921-35. PubMed ID: 15247285
[TBL] [Abstract][Full Text] [Related]
6. Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells.
Das R; Mahabeleshwar GH; Kundu GC
J Biol Chem; 2003 Aug; 278(31):28593-606. PubMed ID: 12771144
[TBL] [Abstract][Full Text] [Related]
7. JNK1 differentially regulates osteopontin-induced nuclear factor-inducing kinase/MEKK1-dependent activating protein-1-mediated promatrix metalloproteinase-9 activation.
Rangaswami H; Bulbule A; Kundu GC
J Biol Chem; 2005 May; 280(19):19381-92. PubMed ID: 15757900
[TBL] [Abstract][Full Text] [Related]
8. Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression.
Das R; Philip S; Mahabeleshwar GH; Bulbule A; Kundu GC
IUBMB Life; 2005 Jun; 57(6):441-7. PubMed ID: 16012053
[TBL] [Abstract][Full Text] [Related]
9. Syk, a protein-tyrosine kinase, suppresses the cell motility and nuclear factor kappa B-mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3'-kinase activity in breast cancer cells.
Mahabeleshwar GH; Kundu GC
J Biol Chem; 2003 Feb; 278(8):6209-21. PubMed ID: 12477728
[TBL] [Abstract][Full Text] [Related]
10. The T-cell antigen receptor utilizes Lck, Raf-1, and MEK-1 for activating mitogen-activated protein kinase. Evidence for the existence of a second protein kinase C-dependent pathway in an Lck-negative Jurkat cell mutant.
Gupta S; Weiss A; Kumar G; Wang S; Nel A
J Biol Chem; 1994 Jun; 269(25):17349-57. PubMed ID: 7516337
[TBL] [Abstract][Full Text] [Related]
11. cAMP potentiates H(2)O(2)-induced ERK1/2 phosphorylation without the requirement for MEK1/2 phosphorylation.
Lee K; Esselman WJ
Cell Signal; 2001 Sep; 13(9):645-52. PubMed ID: 11495722
[TBL] [Abstract][Full Text] [Related]
12. Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor.
Nicholl SM; Roztocil E; Davies MG
J Vasc Surg; 2005 Apr; 41(4):672-81. PubMed ID: 15874933
[TBL] [Abstract][Full Text] [Related]
13. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility.
Nguyen DH; Hussaini IM; Gonias SL
J Biol Chem; 1998 Apr; 273(14):8502-7. PubMed ID: 9525964
[TBL] [Abstract][Full Text] [Related]
14. Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner.
Nguyen DH; Catling AD; Webb DJ; Sankovic M; Walker LA; Somlyo AV; Weber MJ; Gonias SL
J Cell Biol; 1999 Jul; 146(1):149-64. PubMed ID: 10402467
[TBL] [Abstract][Full Text] [Related]
15. Rac1-MKK3-p38-MAPKAPK2 pathway promotes urokinase plasminogen activator mRNA stability in invasive breast cancer cells.
Han Q; Leng J; Bian D; Mahanivong C; Carpenter KA; Pan ZK; Han J; Huang S
J Biol Chem; 2002 Dec; 277(50):48379-85. PubMed ID: 12377770
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
Festuccia C; Angelucci A; Gravina GL; Biordi L; Millimaggi D; Muzi P; Vicentini C; Bologna M
Thromb Haemost; 2005 May; 93(5):964-75. PubMed ID: 15886816
[TBL] [Abstract][Full Text] [Related]
17. Constitutively active Galpha16 stimulates STAT3 via a c-Src/JAK- and ERK-dependent mechanism.
Lo RK; Cheung H; Wong YH
J Biol Chem; 2003 Dec; 278(52):52154-65. PubMed ID: 14551213
[TBL] [Abstract][Full Text] [Related]
18. Cholecystokinin stimulates extracellular signal-regulated kinase through activation of the epidermal growth factor receptor, Yes, and protein kinase C. Signal amplification at the level of Raf by activation of protein kinase Cepsilon.
Piiper A; Elez R; You SJ; Kronenberger B; Loitsch S; Roche S; Zeuzem S
J Biol Chem; 2003 Feb; 278(9):7065-72. PubMed ID: 12496267
[TBL] [Abstract][Full Text] [Related]
19. Nitric oxide and cGMP activate the Ras-MAP kinase pathway-stimulating protein tyrosine phosphorylation in rabbit aortic endothelial cells.
Oliveira CJ; Schindler F; Ventura AM; Morais MS; Arai RJ; Debbas V; Stern A; Monteiro HP
Free Radic Biol Med; 2003 Aug; 35(4):381-96. PubMed ID: 12899940
[TBL] [Abstract][Full Text] [Related]
20. Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator.
Sliva D; Rizzo MT; English D
J Biol Chem; 2002 Feb; 277(5):3150-7. PubMed ID: 11689575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
